A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of DRL-17822 in Patients With Type II Hyperlipidemia.
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2014
At a glance
- Drugs DRL 17822 (Primary)
- Indications Hyperlipoproteinaemia type II
- Focus Therapeutic Use
- Sponsors Dr Reddys Laboratories
- 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Mar 2012 Planned number of patients changed from 168 to 365 as reported by European Clinical Trials Database.
- 29 Mar 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2011-001023-21).